- Stroke: 700,000 per year
- Parkinson’s: 4.5 million prevalence
- Alzheimer’s: 1 million prevalence
- Epilepsy: 200,00 per year
- Traumatic brain injury: 1.4 million prevalence
- Central nervous system and spinal cord disease: 1 million prevalence
Companies with active product development for cell therapy in neurological applications include: Aastrom Bioscience Inc., Aeolus Pharmaceuticals, Aldagen, Inc., Athersys, Inc., BeFutur Biotechnologies, BrainStorm Cell Therapeutics, Inc., co.don AG, ES Cell International, Geron Corporation, Innogenetics, Integra LifeSciences Inc., Living Cell Technologies Ltd., Medtronic, Neuralstem, Inc., NeuroGeneration, Inc., NeuroNova AB, Osteotech, Pluristem Therapeutics, Inc., Polyganics BV, ProNeuron Biotechnologies, Inc., ReInnervate Ltd., ReNeuron Ltd., Sernova Corp., Stem Cell Pharma Inc., StemCells Inc., Targeted Genetics Corporation, TEI Biosciences Inc., Transition Therapeutics Inc, and TriStem Corporation. Data on cell and tissue engineering therapy markets and products under development is provided in MedMarket Diligence Report #S520, “Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018.”